An inconspicuous insect bite as the cause of sepsis in a patient treated with infliximab due to rheumatoid arthritis

Advances in Medical Sciences

Volumn 56, Issue 1, 2011, Pages 106-108

  Zynek Litwin, M ^a   Kuzniar J ^a   Nocen Rychlewska B ^b   Kusztal, M ^a   Klinger, M ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b 51 124   (Poland)

Author keywords

amyloidosis; Infliximab; kidney failure; leucopenia; rheumatoid arthritis; severe sepsis

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CIPROFLOXACIN; CYCLOSPORIN A; FLUCONAZOLE; HUMAN IMMUNOGLOBULIN; HYDROCORTISONE; IMIPENEM; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; VANCOMYCIN;

ADULT; APLASIA; ARTICLE; BLISTER; CASE REPORT; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEVER; GRANULOCYTOPENIA; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; INSECT BITE; JOINT DESTRUCTION; KIDNEY AMYLOIDOSIS; KIDNEY DISEASE; LEUKOPENIA; MALE; MUSCLE HYPOTONIA; NECROSIS; PALLOR; PERIPHERAL EDEMA; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SKIN INFECTION; TACHYCARDIA; THROMBOCYTOPENIA;

EID: 79958226595     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-011-0003-5     Document Type: Article

References (15)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001 Mar 22;344(12):907-16 (Pubitemid 32224400)
2. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594-602
3. Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003 Jul;48(7):2019-24 (Pubitemid 36828697)
4. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932-9
5. Fitzcharles MA, Clayton D, Ménard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol. 2002 Dec;29(12):2525-30 (Pubitemid 35416956)
6. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002 Oct;46(10):2571-3 (Pubitemid 36118918)
7. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005 Jun;34(6):819-36 (Pubitemid 40740207)
8. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med. 2005 May;118(5):515-20 (Pubitemid 40615475)
9. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003 May;42(5):617-21 (Pubitemid 37220869)
10. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002 Jan;78(915):47-8 (Pubitemid 34074917)
11. Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, Yu KW, Wong WW, Liu CY. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect. 2004 Dec;37(6):350-8
12. Teo WY, Chan MY, Lam CM, Chong CY. Skin manifestation of Stenotrophomonas maltophilia infection-a case report and review article. Ann Acad Med Singapore. 2006 Dec;35(12):897-900
13. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003 Aug 5;139(3):W-W63
14. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol. 1997 May;36(5):589-93
15. Kimura Y, Imundo LF, Li SC. High dose Infliximab in the treatment of resistant systemic juvenile rheumatoid arthritis [abstract 1316]. Arthritis Rheum. 2001 Sep;44(suppl 9):S272